The International Testing Agency has informed the Italian cyclist about an abnormal analysis result. The ITA carries out the independent anti-doping programme for the Union Cycliste Internationale.
Sample and substance Linda Laporta
The sample was taken on 5 February 2026 from a targeted testing campaign during the UAE Tour Women. The laboratory detected enobosarm, also known as ostarine. The substance belongs to class S1.2 Other Anabolic Agents of the WADA Prohibited List. Enobosarm is prohibited at all times, both in and out of competition. The substance is considered non-specific and has been shown to increase lean body mass. Enobosarm was developed to treat muscle wasting and osteoporosis. It has an anabolic effect on muscles and bones without the strong side effects of classic steroids, but is not authorised as a drug and is often misused as a doping agent.
Procedure and rights
Laporta has the right to request that the B sample be analysed. If the B sample confirms the result of the A sample, the case is considered a confirmed anti-doping rule violation. Even if the B sample is not analysed, the case will be treated as a confirmed violation. In both cases, the rider may submit an explanation for the result.
Provisional ban for Linda Laporta
A provisional ban was imposed in accordance with the World Anti-Doping Code and Article 7.4.1 of the UCI Anti-Doping Rules. This measure is mandatory for such findings. Laporta can contest the provisional ban and apply for it to be lifted. The UCI has delegated its anti-doping programme to the ITA. The ITA is responsible for the full prosecution of the case. The agency will not make any further comments during the ongoing proceedings.
More news from women's cycling:
Kristian Bauer
Editor
